Literature DB >> 12017345

Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study.

David C Metz1, Geraldine M Ferron, Jeffrey Paul, Mary Beth Turner, Elaine Soffer, Joseph R Pisegna, Wieslaw J Bochenek.   

Abstract

Under normal physiological conditions, gastric acid production is controlled by a negative feedback mechanism. Proton pump inhibitors, such as pantoprazole, inhibit gastric acid secretion by irreversibly binding and inactivating luminally active hydrogen potassium ATPase. Recovery of acid production after treatment with a proton pump inhibitor is driven by new pump synthesis, activation of existing cytoplasmic pumps, or reversal of proton pump inhibition. The authors measured the time course of the inhibition and recovery of acid secretion in healthy volunteers following intravenous administration of pantoprazole to determine the rate of proton pump activation under maximally stimulated conditions. Gastric acid production was measured in 27 Helicobacter pylori negative healthy volunteers (mean age = 31 +/- 7 years; 17 men, 10 women) who received single doses of intravenous pantoprazole (20, 40, 80, or 120 mg) in the presence of a continuous intravenous infusion of 1 ug/kg/h of pentagastrin. From the time profile of acid secretion, the authors described the rate of change of acid output using an irreversible pharmacodynamic response model represented by the equation dR/dt = -k x R x Cpanto + Ln2/PPR x (Ro-R) and correlated the parameter values with demographic factors and gastric acid measurements. Mean stimulated acid output secretion was 21.6 +/- 18.4 mEq/h (range: 1.6-90.5) prior to the administration of pantoprazole and remained steady for 25 hours after placebo administration. Intravenous pantoprazole inhibited acid output in a dose-response fashion, with maximal inhibition (99.9%) occurring after an 80 mg dose. Mean proton pump recovery time was 37.1 +/- 21.0 hours (range: 6.7-75), and recovery was independent of the dose of pantoprazole. There was no association noted between proton pump recovery time and gender, age, race, body weight, or pantoprazole dose. However, there was an inverse correlation between acid output during baseline stimulation and recovery of acid secretion. Mean proton pump recovery time in stimulated normal human volunteers was 37.1 +/- 21.0 hours, with a range of 6.7 to 75 hours. The authors hypothesize that there may be a normal homeostatic mechanism that maintains acid secretory capability within a normal range by altering the rate of proton pump activation dependent on the individual's parietal cell mass. Abnormalities of this process may be responsible for the development of acid peptic disease in susceptible individuals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12017345      PMCID: PMC6719691          DOI: 10.1177/00912700222011562

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  26 in total

Review 1.  The somatostatin receptor in the GI tract.

Authors:  M J Lewin
Journal:  Annu Rev Physiol       Date:  1992       Impact factor: 19.318

2.  The relationship between the acid output of the stomach following "maximal" histamine stimulation and the parietal cell mass.

Authors:  W I CARD; I N MARKS
Journal:  Clin Sci       Date:  1960-02       Impact factor: 6.124

Review 3.  Omeprazole.

Authors:  P N Maton
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

4.  Regulation of rat gastric H+/K(+)-ATPase alpha-subunit mRNA by omeprazole.

Authors:  A Tari; V Wu; M Sumii; G Sachs; J H Walsh
Journal:  Biochim Biophys Acta       Date:  1991-12-02

Review 5.  The mechanism and structure of the gastric H,K-ATPase.

Authors:  E C Rabon; M A Reuben
Journal:  Annu Rev Physiol       Date:  1990       Impact factor: 19.318

6.  PACAP type I receptor activation regulates ECL cells and gastric acid secretion.

Authors:  N Zeng; C Athmann; T Kang; R M Lyu; J H Walsh; G V Ohning; G Sachs; J R Pisegna
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

7.  Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats.

Authors:  G M Ferron; W McKeand; P R Mayer
Journal:  J Clin Pharmacol       Date:  2001-02       Impact factor: 3.126

8.  Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.

Authors:  J R Pisegna; P Martin; W McKeand; G Ohning; J H Walsh; J Paul
Journal:  Am J Gastroenterol       Date:  1999-10       Impact factor: 10.864

9.  Effect of age and Helicobacter pylori infection on gastric acid secretion.

Authors:  K Haruma; T Kamada; H Kawaguchi; S Okamoto; M Yoshihara; K Sumii; M Inoue; S Kishimoto; G Kajiyama; A Miyoshi
Journal:  J Gastroenterol Hepatol       Date:  2000-03       Impact factor: 4.029

10.  Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.

Authors:  E A Lew; J R Pisegna; J A Starr; E F Soffer; C Forsmark; I M Modlin; J H Walsh; M Beg; W Bochenek; D C Metz
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

View more
  7 in total

1.  Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.

Authors:  D C Metz; G M Comer; E Soffer; C E Forsmark; B Cryer; W Chey; J R Pisegna
Journal:  Aliment Pharmacol Ther       Date:  2006-02-01       Impact factor: 8.171

2.  Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.

Authors:  Eric T Wittbrodt; Charles Baum; David A Peura
Journal:  Clin Exp Gastroenterol       Date:  2009-11-17

3.  Comparative anti-ulcerogenic study of pantoprazole formulation with and without sodium bicarbonate buffer on pyloric ligated rat.

Authors:  Papiya Bigoniya; A Shukla; C S Singh; P Gotiya
Journal:  J Pharmacol Pharmacother       Date:  2011-07

4.  Intravenous versus high-dose oral proton pump inhibitor therapy after endoscopic hemostasis of high-risk lesions in patients with acute nonvariceal upper gastrointestinal bleeding.

Authors:  Sanjay Murthy; Leila Keyvani; Shauna Leeson; Laura E Targownik
Journal:  Dig Dis Sci       Date:  2007-03-24       Impact factor: 3.487

Review 5.  Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole.

Authors:  Joseph Mermelstein; Alanna Chait Mermelstein; Maxwell M Chait
Journal:  Clin Exp Gastroenterol       Date:  2016-07-13

6.  Effects of high-dose versus low-dose proton pump inhibitors for treatment of gastrointestinal ulcer bleeding: a meta-analysis of randomized controlled trials.

Authors:  Wei Zhu; Liang Chen; Jian Zhang; Pei Wang
Journal:  J Int Med Res       Date:  2022-04       Impact factor: 1.671

7.  Gastric Hypersecretory States: Investigation and Management.

Authors:  Jennifer Phan; Jihane N Benhammou; Joseph R Pisegna
Journal:  Curr Treat Options Gastroenterol       Date:  2015-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.